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Abstract
Purpose This study was conducted to
examine the atropine eye drop prescription
trend for children diagnosed with myopia,
and to determine the factors associated with
the prescription of atropine eye drops.
Design This was a population-based
cross-sectional study.
Methods This study was conducted using a
national representative sample from the
National Health Insurance (NHI) claims data.
All school children between 4 and 18 years
of age who had visited an ophthalmologist
and were diagnosed with myopia between
2000 and 2007 were included herein. The
main outcome measure was the proportion of
subjects who were prescribed atropine eye
drops in each year. Logistic regression was
used to identify the factors associated with
atropine eye drops being prescribed.
Results The prescription of atropine eye
drops for children diagnosed with myopia
increased significantly from the school years
2000 (36.9%) to 2007 (49.5%). There was also a
shift from prescribing high concentrations
(0.5 and 1%) of atropine eye drops to lower
concentration ones (0.3, 0.25, and 0.1%)
within this period. Atropine eye drops were
more frequently prescribed to 9–12-year-old
children (OR¼ 1.26–1.42, compared with
those 7–8 years old), and to children from
families with a high socioeconomic status
(OR¼ 1.19–1.25); however, they were less
prescribed to those living in mid to low
urbanized areas (OR¼ 0.65–0.84).
Conclusions This study revealed an
increasing trend of atropine eye drop
prescription for children with myopia in
Taiwan. Our study provides eye-care
professionals worldwide a reference for the
potential integration of atropine eye drops
into their clinical practice toward children
with myopia.
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Introduction
Myopia is an important health concern in many
East Asian1–3 and Western countries.4–6
In Taiwan, the prevalence of myopia among 12-
and 13-year-old children is among the highest in
South-East Asia.1,3,7 A trend toward increasing
myopia among 7–18-year-old Taiwanese
children was observed between 1983 and 2000.8
A similar but less extreme trend was found for
12–17 year olds in the United States, depicting
an increase from 25% in 1971–1972 to 41.6% in
1999–2004.5 Given the increasing prevalence and
severity of myopia among children worldwide, a
variety of interventions have been developed to
retard the progression of myopia.9,10 Most of the
proposed interventions lack conclusive evidences
to support their effectiveness.10
Atropine is a nonselective muscarinic
receptor antagonist, which is used to retard
myopia progression among children in South
Eastern Asia. Atropine has become part of
routine eye care in Taiwan ever since the
suggestion by the Taiwan Ophthalmology
Association in the year 2000. Although
evidences from many clinical trials on the use of
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atropine eye drops support a statistically significant
reduction in myopia progression between experimental
and control groups,9–16 the clinical significance of the
results of these trials are controversial. The routine use of
atropine among children with myopia is not
recommended in other countries.10
Aside from the issue of effectiveness, some
ophthalmologists are concerned about the possible long-
term side effects from the use of atropine eye drops,
including phototoxic effects on the retina and lens.10
Others are concerned about near vision blurring,
photophobia, and allergic reaction,12 which could be
lessened by atropine eye drops of lower concentrations.
In treating myopia among children, 0.5% atropine is
more effective than 0.25 and 0.1% atropine.12 One study
found that the clinical effectiveness of higher
concentrations of atropine eye drops is only slightly
higher than lower concentration ones in slowing myopia
progression among children, although the difference
achieved statistical significance.17 However, treatments
with higher concentrations of atropine eye drops are
associated with a higher rate of dropout, higher level of
photophobia due to larger pupil size, and lower
amplitude of accommodation.12,17
The goal of our study is to investigate the prescription
pattern of atropine eye drops among children with
myopia in Taiwan from 2000 to 2007. Taiwanese
ophthalmologists commonly use atropine as a treatment
modality in their daily practice. As no other
recommendations about myopia treatment have been
proposed, it is important to determine the trends in
prescribing atropine by ophthalmologists in Taiwan. This
is because not only do they face one of the highest
percentages of children with myopia, but they also serve
a population with a high progression rate.18 This study
does not intend to discuss whether atropine should be
prescribed to retard the progression of myopia. As
atropine is only one of the methods available for
retarding the progression of myopia, other modalities
should also be considered in clinical practice. Whether or
not to adopt atropine depends not only on the
effectiveness of the treatment and the side effects, but




The National Health Insurance Research Database
(NHIRD) consists of all administrative records of health-
care utilization under the National Health Insurance
(NHI) program in Taiwan. Enrollment in the NHI is
compulsory for all citizens, with a coverage rate of over
99%. The NHI covers all outpatient and inpatient visits.
The data used in this study consist of one million
randomly selected samples from all citizens for the
period from 1 January to 31 December 2005. All citizens
had an equal chance of being selected into the study
sample. This data set is linked to all medical utilization
records of these samples, retrospectively from 2000 and
prospectively to 2008 (which represents the school years
2000–2007). A detailed description of the sampling
method can be found elsewhere.19,20 The National
Health Research Institutes scrambles the individual IDs
before providing the data to scientists in Taiwan for
research purposes to ensure patient privacy. The data set
is divided according to school year rather than calendar
year because of the high correlation between visiting an
ophthalmologist and the annual vision screening
conducted in the schools. In this study, the school
year runs from 2 September of one year to 1 September of
the next year.
Study population
During each school year, we examined individuals aged
between 4 and 18 years to check if they were diagnosed
with myopia. To maintain homogeneity and ensure that
our analysis included only those patients who were
prescribed atropine eye drops for myopia treatment,
individuals with an International Classification of
Diseases, Ninth Clinical Modification diagnosis (ICD-9
CM) of anterior or pan-uveitis (ICD 360.0, 360.1, 091.5,
091.50, 364 (excluding 364.5, 364.6), 053.22, 054.44, 091.52,
098.41), accommodative esotropia (ICD 378.35),
malignant glaucoma (ICD 365.83), and inflammatory
glaucoma (ICD 365.62) were excluded (669 children,
0.03%). Those being prescribed atropine ointment were
excluded (1258 children, 0.06%). In addition, individuals
with incomplete data (6253 children, 0.28%) were also
excluded.
Myopia is defined using ICD-9-CM as ICD 367. We
used ICD 367 instead of the more specific diagnosis of
367.1 for myopia, as physicians normally categorize
myopia diagnosis under category 367, and thus limiting
the diagnoses to 367.1 would exclude a number of
children who were considered having myopia. In this
study, only 62.9% of children who were prescribed
atropine eye drops were diagnosed under category 367.1,
and thus if we use specific diagnosis, approximately one-
third of children being prescribed atropine would be
excluded from this study. By using ICD 367 to define
myopia, 89.5% of all children prescribed atropine eye
drops would be included. Sensitivity analysis showed
that the results are similar for these two definitions of
myopia diagnosis (table not shown).
Atropine prescription for children in Taiwan




The school grade of the pupil was calculated from their
birthday for each of the school years being analyzed.
Grade 1 pupils in elementary school were assigned to be
age 7 years, whereas those in grade 6 in elementary
schools were 12 years old. Children were categorized into
six age groups, corresponding to the ages in kindergarten
(4–6 years old), elementary school (7–8, 9–10, and 11–12
years old), junior high school (13–15 years old), and
senior high school (16–18 years old). The level of
urbanization was determined by the residential area code
of the subjects. There are 361 different administrative
areas within Taiwan. They are grouped into three strata
according to their level of urbanization, based on their
administrative classification. Level 1 includes
metropolitan cities such as Taipei City, Taichung City,
and Kaohsiung City. Level 2 includes other cities and
counties. Level 3 consists of townships and represents
any rural areas.
Socioeconomic status (SES) was classified according to
the monthly wage of the child’s parent or guardian and
was divided into three categories, namely NTD Z40 000,
NTD 20 000–39 999 NTD, and NTD o20 000 (1 USD¼ 30
NTD in May 2012). Those without a well-defined
monthly wage were categorized into two groups: first
farmers and fishermen and second low-income
individuals enrolled in the NHI through local
government offices. The latter consists of mostly
unemployed individuals.
Five different concentrations of atropine eye drops are
currently reimbursed under the NHI program. The 0.5
and 1% atropine formulations have been available for
reimbursement since 1995, the 0.3% formulation since
2001, and the 0.1% formulation since 2004.
Statistical analysis
The unit of observation was the individual child during
each school year. We first analyzed the trend of
ophthalmology visits among 4–18 year olds during the
study period (Figure 1). From the children who visited
ophthalmologists and had a diagnosis of ICD-9 CM 367,
we analyzed the proportion who were being prescribed
atropine eye drops (Figure 2). The trend of the various
concentrations being prescribed is shown in Figure 3. The
proportion of atropine prescribed was calculated by
dividing ‘the number of subjects with a myopia diagnosis
who had received at least one prescription for atropine
eye drops in each analytic stratum during a specific
school year’ by ‘the total number of subjects with a
myopia diagnosis in each analytic stratum during a
specific school year’. We applied multiple logistic
regression analysis to determine the factors associated
with the prescription of atropine eye drops. A subject
was coded 1 if s/he had ever been prescribed atropine
during the study period, and 0 otherwise.
Results
There was an overall 68.3% increase in ophthalmologist
visits for 4–18 year olds from 2000 to 2007 (see Figure 1)
Among them, B85% (85.1, 86.2, and 87.8% in 2000, 2004,
and 2007, respectively) were diagnosed as ‘Disorders
of refraction and accommodation’ (ICD-9 CM 367).
There was no difference among the different age groups.
Children who were diagnosed with ICD-9 367 showed an
Figure 1 Children who visited ophthalmologist (%) during
the school years 2000, 2004, and 2007. For all 4- to 18-year-old
children, the percentage of children who visited ophthalmologist
had significantly increased from 12.7% in 2000 to 18.5% in
2004 and to 21.4% in 2007. For 10-year-old children, the
percentage of children who visited ophthalmologist had
significantly increased from 20.9% in 2000 to 30.7% in 2004
and to 36.1% in 2007.
Figure 2 Atropine eye drop prescription (%) among children
diagnosed with myopia.
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increasing trend for atropine eye drop prescription
(Figure 2). This figure shows an inverted U-shaped
relationship between age and atropine prescription,
with the highest rate for the 9–12 year olds. The
trends associated with prescriptions of different
concentrations of atropine eye drops are shown in
Figure 3. The prescriptions of 0.5 and 1.0% atropine
decreased after 2004, whereas the 0.3%/0.25%
atropine prescriptions increased steadily from
2001 and 2004 onwards, respectively. After 2004,
there was a sharp increase in the prescription of 0.1%
atropine.
The pattern of atropine prescription for different study
variables is shown in Table 1. The factors associated with
atropine prescription for children diagnosed with
myopia are listed in Table 2. Children aged 13–15 years
(OR¼ 0.73, 95% CI¼ 0.71–0.75, Po0.0001) and 16–18
years (OR¼ 0.40, 95% CI¼ 0.39–0.42, Po0.0001) had
lower odds of being prescribed atropine eye drops
compared with the younger primary school students
(aged 7–8 years). Boys and girls were being prescribed
atropine on an equal basis (OR¼ 1.01, 95% CI¼ 0.99–1.02,
P¼ 0.484). Children of parents with a high SES (monthly
wage NTD Z40 000) had a higher odds ratio of being
prescribed atropine (OR¼ 1.22, 95% CI¼ 1.19–1.25,
Po0.0001), whereas children whose parents or guardians
were farmers or fishermen had a lower odds (OR¼ 0.89,
95% CI 0.86–0.92, Po0.0001) compared with children
whose guardians had a monthly wage of NTD o20 000.
Children living in areas with mid to low levels of
urbanization were less likely to be prescribed atropine
compared with those living in high urbanization areas
(OR¼ 0.83 and 0.67 respectively, both Po0.0001).
Discussion
The NHI claims data allow us to investigate the trend of
atropine prescription using a national representative
sample of all individuals over a long period of time
(2000–2007). Population-based information of drug
utilization in such a large scale is rarely available in other
countries. The high prevalence rate of myopia among
Taiwanese children renders Taiwan a good candidate
suitable for such investigation. This research identified
the increasing trend of atropine eye drop prescription for
school children aged 4–18 years who were diagnosed
with myopia between 2000 and 2007, with a concurrent
shift from prescribing high to low concentrations of
atropine eye drops.
If our results are linked to previous epidemiological
studies, the prevalence of myopia (cycloplegic refraction
of less than  0.25D),8,21 remained relatively unchanged
from 2000 to 2006 among 7-year-old students (20% in
2000 and 2006), among 12-year-old students (61% in 2000
and 62% in 2006) and among junior and senior high
school students (B76 and 85%, respectively). However,
although the prevalence of myopia did not change a
great deal, the rate for 4- to 18-year-old children visiting
ophthalmologists increased significantly from 12.7% in
2000 to 20.1% in 2006. (Figure 1) This trend might be
related to the annual vision screening of primary and
secondary school students, as required by the Ministry of
Education as part of the ‘Enforcement of the Children
Eye Health Act’. According to a technical report from the
Ministry of Education in 2004, the trend of children who
failed the vision screening to visit an ophthalmologist for
further evaluation had increased from 84.7% in school
Figure 3 The trends of various concentrations of atropine eye drop prescription among 4–18-year-old children diagnosed with
myopia (2000 to 2007).
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year 2000 to 95.0% in school year 2003. While around
85% of the children who visited an ophthalmologist were
diagnosed with ICD-9 CM 367 (the broader definition of
myopia), the reason for consulting an eye doctor
remained relatively unchanged during the study period.
The odds for myopic children visiting an
ophthalmologist in Taiwan to being prescribed atropine
eye drops increased by 34% between 2000 (36.9%) and
2007 (49.5%). This substantial increase in atropine
prescription might be because of the increased use of
lower concentration of atropine, which produces a lower
level of photophobia and near blurring.12 The rate of
atropine prescriptions for all 4–18-year-old children in
Taiwan increased 2.29-fold from 4.5% in 2000 to 10.3% in
2007 (table not shown). Therefore, the above evidences
allow us to deduce that both the increasing rate of
ophthalmologist visiting and the increasing rate of
atropine prescription from ophthalmologist consist of the
two key components of the increasing trend of atropine
prescription for all children in Taiwan.
Most ophthalmologists would agree that age is an
important consideration when treating myopia.
Although in most clinical studies atropine is used to treat
6–13-year-old children,11–15 in Taiwan, 41.6% of 13–15-
year-old children (junior high school students) and 28.5%
of 16–18-year-old children (senior high school students)
were still being prescribed atropine during 2007. The
present study shows that atropine remains being
prescribed to a certain portion of 13–18-year-old children,
indicating that doctors are still concerned about myopia
progression in these age groups. Different from studies in
Hong Kong and Singapore school children that showed
highest myopic progression in primary school
students,22,23 Shih et al18 reported that junior high school
students had a higher progression rate than primary
school students and senior high school students in
Taiwan. Further studies of this 13–18-year-old group are
needed to reveal the effectiveness of atropine as a means
of decreasing myopia progression.
Prior studies in Taiwan indicate that higher degree of
urbanization is associated with the higher prevalence,8,24
Table 1 Atropine eye drop a prescription (%) among children
diagnosed with myopiab during school years 2000 to 2007 in
Taiwan
Variables
School year 2000 2004 2007 2000–2007
Number of children 22 417 32 709 36 058 240 739
Atropine eye drops (%) 36.9 44.2 49.5 43.9
Age group (%)
4–6 28.1 31.2 35.1 31.6
7–8 37.7 45.6 51.2 44.8
9–10 44.8 52.2 59.7 52.9
11–12 42.4 52.1 57.6 51.0
13–15 31.1 38.1 41.6 37.2
16–18 20.5 25.1 28.5 25.1
Gender (%)
Boys 37.1 44.4 49.4 44.0
Girls 36.8 44.1 49.7 43.7
Socioeconomic status (%)
NTDc o20 000 36.5 43.8 49.1 43.4
NTD 20 000–39 999 36.4 43.8 49.2 43.5
NTD Z40 000 41.8 49.6 55.7 49.2
Farmers and fishermen 30.4 37.5 43.5 37.2
Othersd 34.1 40.4 44.4 40.3
Urbanization level (%)
Level 1 43.0 49.7 55.3 49.5
Level 2 37.8 44.7 49.2 44.1
Level 3 29.7 38.7 44.9 38.4
To conserve space, only data of total year (2000 to 2007) and school years
2000, 2004, and 2007 are shown; data of other years are available on
request.
a Atropine eye drops include: 1% atropine, 0.5% atropine, 0.3% atropine,
0.25% atropine, and 0.1% atropine eye drop.
b We used a broader definition of myopia (ICD-9-CM as 367) in this study.
c NTD is New Taiwan Dollar (1 USDA30 NTD).
d Others: low-income family or individuals who have no regular job.
Table 2 Multiple logistic regression for factors associated with
atropine eye dropa prescription (n¼ 240 739)
Atropine eye drop prescription
ORb 95% CI P-value
Variables
Age
4–6 0.56 0.54-0.58 o0.0001
7–8 1.00
9–10 1.38 1.35-1.42 o0.0001
11–12 1.29 1.26-1.32 o0.0001
13–15 0.73 0.71-0.75 o0.0001
16–18 0.40 0.39-0.42 o0.0001
Gender
Boy 1.00
Girl 1.01 0.99-1.02 0.4843
Socioeconomic status
NTDc o20 000 1.00
NTD 20 000–39 999 0.99 0.96-1.01 0.2661
NTD Z40 000 1.22 1.19-1.25 o0.0001
Farmers and fishermen 0.89 0.86-0.92 o0.0001
Othersd 0.86 0.84-0.89 o0.0001
Urbanization level
Level 1 1.00
Level 2 0.83 0.81-0.84 o0.0001
Level 3 0.67 0.65-0.68 o0.0001
a Atropine eye drops include: 1% atropine, 0.5% atropine, 0.3% atropine,
0.25% atropine, and 0.1% atropine eye drop.
b The OR represented the adjusted OR. The full model included the
following variables: age groups, gender, socioeconomic status, urbaniza-
tion level, and school years.
c NTD is New Taiwan Dollar (1 USDA30 NTD).
d Others: low-income family or individuals who have no regular job.
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and higher progression rate of myopia.18 In the same
token, myopia is highly associated with atropine
prescription. In our study, we discovered that higher
levels of urbanization were found to be significantly
associated with a higher rate of atropine prescription
when compared with a lower level of urbanization. It is
possible that this is not only associated with the
progression rate of myopia,18 but also with the
severity of myopia, and/or the medical resources
available in the various areas with different urbanization
levels.
In our study, children of high SES families tended to be
prescribed atropine more often. Studies have shown that
adults with a high SES tend to be associated with a
higher myopic refraction.25 It is well known that the
refractive status of parents influences their children’s
myopia26 through either hereditary or environmental
factors.27–29 A strong parental history of myopia is
associated with faster eye growth and a myopic shift.30
Therefore, children from a high socioeconomic
background may have a higher prevalence of myopia
and faster myopic progression, which justifies a higher
level of prescription of atropine. Alternatively, these
children may also have a weaker economic barrier to
ophthalmology outpatient visits and thus have a greater
chance of being treated.
This study also has some limitations, which must be
borne in mind while interpreting the study result. First,
although dilution of the atropine eye drops by medical
institutions is not allowed under NHI regulations, we
still cannot neglect the possible cases of drug dilutions.
Lee et al31 pointed out that using 0.05% atropine eye
drops is still effective in retarding the rate of myopia
progression. It is possible that some institutions prescribe
high concentration of eye drops for patients, but which
are then diluted to a lower concentration in practice.
Nevertheless, this should not result in significant bias if
we assume that this phenomenon is constant across the
years. In addition, if dilution was considered, only high
concentrations of eye drops can be diluted to low
concentration ones, and not the reverse. Thus, the shift
from high to low concentration of atropine for actual use
would be more significant if the actual concentration
would be measured. Second, we are unable to measure
drug compliance, which is beyond the scope of this
study. Poor compliance is an important issue for all
chronic diseases. Our data are reimbursed records; thus,
it only shows the trend for prescribing atropine eye
drops by ophthalmologists. Finally, other treatment
modalities such as multifocal lenses, contact lenses,
orthokeratology, acupuncture, or traditional medicine
used for halting myopia progression are not covered
under the NHI program, and thus cannot be evaluated in
this study. Consequently, we could not determine
whether there were combined uses or other treatments
that involved these treatment modalities.
This study concludes that a number of
ophthalmologists in Taiwan considered that this drug
could be used to retard myopia progression in children.
The increased prescription trend might also be related to
a greater concern by parents about their children’s eye
health and the availability of lower concentration of
atropine eye drops. Further studies on the long-term
effects of atropine on the retina and lens are still needed.
We will like to reinforce that the use of atropine among
children 13–18 years of age should be based on clinically
supported evidence rather than mere speculation.
Nonetheless, based on this study, other governments and
policy makers worldwide are now in a better position
when considering the integration of atropine as a
treatment modality in their countries.
Summary
What is known about this topic
K Atropine is a modality for halting myopia progression in
children.
K Although higher concentrations of atropine eye drops are
associated with better efficacy, clinical studies have
shown that those who are prescribed higher concentration
experience higher withdrawal rate.
What this study adds
K The real prescription pattern of atropine eye drops
increased from 2000 to 2007 in Taiwan; and the
prescription of atropine eye drops shifted from high to
low concentration during this period.
K Atropine eye drops were more frequently prescribed to
9–12-year-old children, children living in highly
urbanized areas, and children from families with a high
socioeconomic status.
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